- Titre
- Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, for Treatment of Rheumatoid Arthritis With an Inadequate Response to One or More Disease-Modifying Antirheumatic Drugs: Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1/11 Study
- Créateurs - sans rôle
- Mikkel Østergaard - Copenhagen University Hospitals at Hvidovre and Glostrup, Copenhagen, DenmarkBo Baslund - National University Hospital, Copenhagen, DenmarkJørgen Petersen - Genmab, Copenhagen, DenmarkStanislaw Sierakowski - Medical Academy of Bialystok, Bialystok, PolandWilliam Rigby - Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United StatesBernadette Rojkovich - Polyclinic of the Hospital Brothers of St. John of God in Budapest, Budapest, HungaryChristian Jorgensen - Lapeyronie University Hospital, Montpellier, FrancePeter T Dawes - The Haywood Hospital, Stoke on Trent, United KingdomCharlotte Wiell - Copenhagen University Hospital at Hvidovre, Copenhagen, DenmarkDaniel J Wallace - Wallace Rheumatic Study Center, Los Angeles, California, United StatesSøren C Tamer - Genmab, Copenhagen, DenmarkHelle Kastberg - Genmab, Copenhagen, Denmark
- Détails de publication
- Arthritis and rheumatism, Vol.62(8), pp.2227-2238
- Éditeur
- Wiley
- Identifiants
- 99141222309311
- Unité académique
- Cell souches plasticité cellul régénérat tissulaire immuno des maladies inflamm - IRMB
- Langue
- English
- Type de ressource
- Journal article
Article de revue
Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, for Treatment of Rheumatoid Arthritis With an Inadequate Response to One or More Disease-Modifying Antirheumatic Drugs: Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1/11 Study
Arthritis and rheumatism, Vol.62(8), pp.2227-2238
2010
Indicateurs
1 Consultations de la notice